Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Serum β 2-Microglobulin Levels in Patients Chronically Dialyzed with CA-210 versus CT-190 Dialysis Membranes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          β<sub>2</sub>-Microglobulin (B<sub>2</sub>M) amyloidosis (dialysis-related amyloidosis), manifested primarily by carpal tunnel syndrome and destructive osteoarthropathy, is a major sequel of long-term dialysis. Previous investigators have shown that high-flux biocompatible synthetic membranes (e.g., polyacrylonitrile) lower β<sub>2</sub>M levels when compared to cellulosic membranes (e.g., cuprophane). To date, however, no study has compared β<sub>2</sub>M levels of patients dialyzed with the two more biocompatible cellulosic membranes CA-210 (cellulose acetate) and CT-190 (cellulose triacetate; high flux, more biocompatible). We retrospectively compared the serum β<sub>2</sub>M levels in two chronic hemodialysis populations: 22 patients on CT-190 and 21 patients on CA-210. There was no difference between the two groups with regard to age, sex, or duration of dialysis. The patients on the CA-210 membrane had significantly higher serum β<sub>2</sub>M levels (mean ± SE; 53.6 ± 4.7 vs. 36.8 ± 2.6 mg/l, CA-210 vs. CT-190, respectively, p = 0.003). Subsequently we switched 13 patients dialyzed with a CA-210 membrane to a CT-190 membrane and followed serum β<sub>2</sub>M levels for 14 months. We found a significant decrease in serum β<sub>2</sub>M levels within 1 month which was maintained over 14 months of follow-up (47.4 ± 4.4 vs. 62.8 ± 6.7 mg/l, CT-190 at 14 months vs. CA-210 at baseline, respectively, p < 0.01).

          Related collections

          Author and article information

          Journal
          AJN
          Am J Nephrol
          10.1159/issn.0250-8095
          American Journal of Nephrology
          S. Karger AG
          0250-8095
          1421-9670
          1998
          February 1998
          16 January 1998
          : 18
          : 1
          : 16-20
          Affiliations
          Division of Nephrology, St. Louis University Health Sciences Center, St. Louis, Mo., USA
          Article
          13299 Am J Nephrol 1998;18:16–20
          10.1159/000013299
          9481434
          © 1998 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 3, Tables: 1, References: 27, Pages: 5
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/13299
          Categories
          Clinical Study

          Cardiovascular Medicine, Nephrology

          Hemodialysis, Amyloid, β2-Microglobulin, Osteodystrophy

          Comments

          Comment on this article